Cargando…

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study

SIMPLE SUMMARY: Advanced triple-negative breast cancer (TNBC) remains an extremely challenging situation in oncology, where new therapeutical strategies are desperately needed. Immunotherapy has opened a window of opportunity in this setting, with some promising results with chemo-immunotherapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	de la Cruz-Merino, Luis, Gion, María, Cruz-Jurado, Josefina, Quiroga, Vanesa, Andrés, Raquel, Moreno, Fernando, Alonso-Romero, Jose L., Ramos, Manuel, Holgado, Esther, Cortés, Javier, López-Miranda, Elena, Henao-Carrasco, Fernando, Palazón-Carrión, Natalia, Rodríguez, Luz M., Ceballos, Isaac, Casas, Maribel, Benito, Sara, Chiesa, Massimo, Bezares, Susana, Caballero, Rosalia, Jiménez-Cortegana, Carlos, Sánchez-Margalet, Víctor, Rojo, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582406/ https://www.ncbi.nlm.nih.gov/pubmed/34771596 http://dx.doi.org/10.3390/cancers13215432

Ejemplares similares

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
por: de la Cruz-Merino, L., et al.
Publicado: (2022)

Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
por: Palazón-Carrión, Natalia, et al.
Publicado: (2021)

Publisher Correction: Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
por: Palazón‑Carrión, Natalia, et al.
Publicado: (2021)

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
por: Ayala de la Peña, Francisco, et al.
Publicado: (2023)

GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID‐19 Pandemic in Spain
por: Martin, Miguel, et al.
Publicado: (2020)

SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
por: Garcia-Saenz, Jose Angel, et al.
Publicado: (2023)

Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
por: Garcia-Saenz, Jose Angel, et al.
Publicado: (2023)

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
por: Ocana, Alberto, et al.
Publicado: (2017)

Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy
por: Sánchez-Margalet, Víctor, et al.
Publicado: (2019)

Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial
por: Jiménez-Cortegana, Carlos, et al.
Publicado: (2021)

Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
por: García-Domínguez, Daniel J., et al.
Publicado: (2022)

Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study
por: Fernández de Larrea-Baz, Nerea, et al.
Publicado: (2020)

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial
por: Martin, Miguel, et al.
Publicado: (2014)

Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case–control EpiGEICAM study
por: Castelló, A, et al.
Publicado: (2014)

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study
por: Barnadas, A., et al.
Publicado: (2019)

The emblematic South African therocephalian Euchambersia in China: a new link in the dispersal of late Permian vertebrates across Pangea
por: Liu, Jun, et al.
Publicado: (2022)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
por: Alba, E, et al.
Publicado: (2014)

Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study
por: Márquez-Rodas, Iván, et al.
Publicado: (2017)

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
por: Lopez-Tarruella, Sara, et al.
Publicado: (2019)

Catastrophic slab loss in southwestern Pangea preserved in the mantle and igneous record
por: Gianni, Guido M., et al.
Publicado: (2022)

Obesity and Risk for Lymphoma: Possible Role of Leptin
por: Jiménez-Cortegana, Carlos, et al.
Publicado: (2022)

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study
por: de Dueñas, Eduardo Martínez, et al.
Publicado: (2014)

PanGEA: Identification of allele specific gene expression using the 454 technology
por: Kofler, Robert, et al.
Publicado: (2009)

Ambient Agents: Embedded Agents for Remote Control and Monitoring Using the PANGEA Platform
por: Villarrubia, Gabriel, et al.
Publicado: (2014)

Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study
por: Lope, Virginia, et al.
Publicado: (2022)

Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells
por: Sánchez-León, María Luisa, et al.
Publicado: (2023)

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
por: Lluch, Ana, et al.
Publicado: (2020)

Prevalence of acute critical neurological disease in children: a global epidemiological assessment (PANGEA)
por: Fink, E, et al.
Publicado: (2013)

Author Correction: Catastrophic slab loss in southwestern Pangea preserved in the mantle and igneous record
por: Gianni, Guido M., et al.
Publicado: (2022)

PANGEA: A New Gene Set Enrichment Tool for Drosophila and Common Research Organisms
por: Hu, Yanhui, et al.
Publicado: (2023)

PANGEA: a new gene set enrichment tool for Drosophila and common research organisms
por: Hu, Yanhui, et al.
Publicado: (2023)

Is there a role for immunotherapy in HER2-positive breast cancer?
por: Holgado, Esther, et al.
Publicado: (2018)

Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
por: Martín, Miguel, et al.
Publicado: (2023)

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
por: Martin, Miguel, et al.
Publicado: (2016)

Pangea breakup and northward drift of the Indian subcontinent reproduced by a numerical model of mantle convection
por: Yoshida, Masaki, et al.
Publicado: (2015)

Phylogenetic Tools for Generalized HIV-1 Epidemics: Findings from the PANGEA-HIV Methods Comparison
por: Ratmann, Oliver, et al.
Publicado: (2017)

Mercury evidence from southern Pangea terrestrial sections for end-Permian global volcanic effects
por: Shen, Jun, et al.
Publicado: (2023)

Synapsid tracks with skin impressions illuminate the terrestrial tetrapod diversity in the earliest Permian of equatorial Pangea
por: Calábková, Gabriela, et al.
Publicado: (2023)

Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report
por: García, Francisco José Valdivia, et al.
Publicado: (2020)

Obesity and Breast Cancer: Role of Leptin
por: Sánchez-Jiménez, Flora, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1bnfja82snkihbnm77puhvdllr